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ABSTRACT 
Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus (MRSA) 
by 
Ilene Bautista 
Linda D. Stetzenbach, Ph.D., Committee Chair 
Professor, Department of Environmental and Occupational Health 
School of Community Health and Sciences 
University of Nevada, Las Vegas 
Staphylococcus aureus is a frequent cause of a myriad of infections in hospitals, 
healthcare facilities and community settings. It is often related to skin and soft tissue 
infection, but it can also cause other diseases varying from food poisoning to endocarditis 
and toxic shock syndrome. According to a study by Kuehnert et al. (2006) there has been 
a strong association between Staphylococcus aureus (S. aureus) carriage and risk factors 
for subsequent infections. Subsequent infection from S. aureus, including methicillin-
resistant S. aureus (MRSA) infection, can be projected by looking at the presence of S. 
aureus nasal colonization. The purpose of this study was to determine the prevalence of 
MRSA among adult patients and assess the antimicrobial susceptibility pattern of isolated 
samples. Specimens were collected from a Las Vegas county hospital during a four-
month period from September 2008 through December 2008. Patient demographics and 
nasal swabs were collected upon admission from screened patients regarded to be at high 
risk for MRSA colonization. Antimicrobial-susceptibility testing and strain typing were 
performed. A total of 100 MRSA samples were processed for this study. Among the 
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MRSA positive samples studied, the average patient age was 58 years, predominantly in 
Whites (64%) and mostly in male (69%). All isolates showed susceptibility to 
quinipristin/dalfopristin and vancomycin, 99% to rifampin, 96% to linezolid, and 83% to 
tetracycline and trimetoprim-sulfamethoxazole. Predominant strain types were USA 100 
USA300, Brazilian and Iberian. Increased assessment of the population dynamics of 
MRSA colonization can assist in determining the extent of MRSA prevalence, aid 
appropriate treatment, identify interventions, and prevent transmission in the population. 
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CHAPTER 1 
INTRODUCTION 
Prior to the development of antibiotics, infection with Staphylococcus aureus was 
often fatal; now Staphylococcus aureus usually responds to numerous antimicrobial 
agents (Kuehnert et al, 2006). However, as the number of multidrug-resistant strains of S. 
aureus continues to increase, particularly methicillin-resistant Staphylococcus aureus 
(MRS A), treatment of this infection has been challenging. Recent 2005 nationwide 
estimates of MRSA invasive disease involved 94,360 cases and 18,650 deaths (Klevens 
et al, 2007). 
Staphylococcus aureus is a gram positive coccus bacterium that is usually carried on 
the skin and the nose of healthy people. 5". aureus infection frequently involves the skin 
and soft tissue but it can also cause other life-threatening systemic illnesses including 
endocarditis, meningitis, and toxic shock syndrome. Treatment of early infections usually 
involves incising and draining the lesion supplemented by beta-lactam antibiotic drugs 
(McCaige/a/.,2006). 
Background 
S. aureus has numerous properties that are believed to play a part in its ability to 
cause disease (Koneman et al., 1997). Some strains produce an exopolysacharide capsule 
or slime layer that prevents it from being consumed by the body's immune system. Its 
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cell wall contains teichoic acids that help it adhere to mucosal surfaces. Enzymes such as 
hyaluronidase and lipases that lyse the intracellular matrix in tissues allowing it to spread 
and digest the host cell membranes. S. aureus also secretes leucocidins, such as Panton-
Valentine Leukocidin (PVL), an exotoxin that creates holes in white blood cell 
membranes causing them to swell and lyse. The presence of PVL gene has been used as a 
marker for community-associated MRSA. Another toxin involved in S. aurues virulence 
is toxic shock syndrome toxin (TSST) which causes the release of numerous cell 
signaling complexes resulting in organ failure, hypovolemic shock, or tissue hypoxia 
which can lead to rapid death (Koneman et al., 1997). 
The first reported case of MRSA emerged from the United Kingdom in 1961 (Huang 
et al., 2006), only a year after the introduction of methicillin. It has since spread to 
Europe, Japan, and Australia. In 1968, the first case of MRSA was first reported in the 
United States (Huang el al, 2006). In 1972, only two percent of S. aureus were drug 
resistant. By 1995 the percentage rose to 22%, and in 2004 the rate rose to 63% (Klevens 
et al., 2005). 
Antimicrobial resistance takes place when bacteria change or adapt in a way that 
allows them to survive in the presence of antibiotics designed to kill them. Once strains 
of bacteria surpass the deadly effects of antibiotics, they will probably pass on the genes 
for resistance to other bacteria. The mechanism of resistance to methicillin was 
discovered with the identification of reduced-affinity penicillin-binding protein (PBP) in 
MRSA (Deresinski, 2005). Normal PBP helps stop the synthesis of bacterial cell walls; 
however, the altered PBP (PBP2A) in MRSA is blocked. This allows continued bacterial 
multiplication. PBP2A is encoded by the mecA gene which is in the genomic site of the 
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staphylococcal cassette chromosome mec (SCCmec). SCCmec has been discovered to 
contain other genetic elements which encode for resistance to methicillin (Deresinski, 
2005). 
MRSA infections occur more often among those who have had an invasive medical 
procedure, or who have weakened immune systems, or are being treated in hospitals and 
health care facilities (MRSA in Healthcare Settings, 2007). Healthcare related MRSA 
infections typically are serious surgical wound infections, blood stream infections, and 
pneumonia. Currently, MRSA infection has been increasingly found outside healthcare 
facilities, infecting otherwise healthy individuals in the community. Community related 
infections are less severe, usually appearing as pimples and boils (Klevens et al., 2007). 
Hospital-Associated MRSA 
Today, MRSA has been categorized as either hospital-associated (HA-MRSA) or 
community-associated (CA-MRSA). Hospital-associated MRSA has been reported 
among patients with certain risk factors including recent hospitalization, dialysis, 
residence in a long term care facility, presence of invasive devices and history of MRSA 
infection and colonization (Klevens et al., 2007). HA-MRSA can cause a variety of 
diseases from mild intermittent abscesses to life threatening systemic diseases. In 
addition these isolates are also typically resistant to multiple, non beta-lactam antibiotics 
(Fey et al, 2003). 
The predominant pulse-field electrophoresis strain types seen among HA-MRSA are 
USA100, USA200, USA600, USA700, USA800 and less often USA500 (Klevens et al., 
2007; Buck et al, 2005; McDougal et al, 2003). Other markers such as the presence of 
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SCCmec I, II and III, agr group II, and low PVL carriage have been used to distinguish 
HA-MRSA from CA-MRSA. Pulse-field gel electrophoresis (PFGE) genotyping aids in 
determining bacterial isolate identification by acting as DNA "fingerprinting." In 
epidemiology, genotyping is used to help in tracking the spread of infections, monitor 
trends in types, and track seasonal outbreaks (Healy et al, 2005). 
Community-Associated MRSA 
Community-associated MRSA has been described in patients without the established 
healthcare risk factors. CA-MRSA was first described occurring in specific populations 
with distinctive risk factors such as prisoners, intravenous drug users, athletes, military 
trainees, and men who have sex with men (McCaig et al., 2006; Kazakova et al., 2005; 
Zinderman, 2004). This organism usually presents as skin and soft tissue infections. CA-
MRSA isolates are likely to be resistant to fewer antibiotics, produce different toxins, and 
have genetically distinct gene complexes compared to HA-MRSA (McCaig et al., 2006). 
Genetic markers such as SCCmec IV, agr group I, and high PVL gene carriage have been 
used to distinguish CA-MRSA from HA-MRSA (Tsuji et al, 2007). Strains most 
frequently isolated from MRSA infection of community origin include PFGE USA300, 
USA400, USA1000, and USA1100 (Klevens et al, 2007). 
Epidemic MRSA 
MRSA is also a leading cause of nosocomial infection worldwide. Molecular 
epidemiology studies indicate that the massive geographic spread of MRSA resulted from 
the dissemination of relatively few highly epidemic clones. Five major lineage have been 
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defined which were mainly disseminated in southern and eastern Europe, Latin America, 
and the USA (Oliveira et ai, 2002). The five major MRSA lineages are Iberian, 
Brazilian, Hungarian, New York/Japan, and pediatric (Stefani & Varaldo, 2003). The 
continuing dissemination of these lineages indicate that they are successful in terms of 
ability to cause infection, to persist, and to spread from one geographic site to another, 
including across continents (Oliveira et ai, 2002). 
Significance 
According to a nationwide study done by Kuehnert et al. (2005) there were 126,000 
estimated hospitalizations annually related to MRSA. Serious MRSA infections occur in 
approximately 94,000 individuals annually; leading to 19,000 deaths (Klevens et ai, 
2007). Healthcare-associated MRSA accounts for 86% of these cases and 14% are 
community-associated. 
It is estimated that 25% to 30% of the population is colonized in the nose with S. 
aureus (Koneman et ai, 1997). Colonization occur when bacteria are present, but not 
causing an infection. Infection occurs when the bacteria is present, and is causing illness. 
While S. aureus colonize the nose of 25% to 30% of the population, MRSA exists in 
approximately 1.5% of the population (Tenover et ai, 2008). Colonization with S. 
aureus, particularly the nares, has been strongly associated as a risk factor for subsequent 
S. aureus infection (Kuehnert et ai, 2006; Tenover et ai, 2008). Subsequent infection 
from S. aureus, including MRSA infection, can be projected by looking at the presence of 
S. aureus nasal colonization. 
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Data was collected on healthy, non-institutionalized (i.e. not in hospitals, long-term 
care facilities, or prisons) adults from 2001-2004 as part of the NHANES (National 
Health and Nutrition Examination Survey) a survey research program conducted by the 
NCHS (National Center for Health Statistics) of the CDC (Center for Disease Control 
and Prevention). Comparing the data gathered from 2001-2002 and 2003-2004. S. aureus 
colonization decreased from 32.4 % to 28.6% (95% CI = 27.2 to 30.0; p < 0.01); while 
the prevalence of MRSA colonization increased from 0.8 % to 1.5% (95% CI = 1.2 to 
1.8; p < 0.05) (Tenover et al, 2008). 
MRSA was traditionally regarded as a pathogen seen only in the healthcare settings, 
but in the last decades it has appeared in the community. The spread of multi-drug 
resistant S. aureus in the health care setting have made the infection challenging and 
costly to treat. According to a report from Healthcare Cost and Utilization Project MRSA 
hospitalization cost was nearly double that for an MRSA stay compared to stay without 
MRSA infection (Elixhauser & Steiner, 2007). 
As of October 1, 2008, new Medicare regulations will no longer pay hospitals at a 
higher rate for treatment of some conditions that are acquired during a hospital stay 
(Schwab, 2008). One of the reports on Medicare reforms finds that these new regulations 
will have a significant impact on antibiotic prescribing and infection control practices. 
One third of the physicians who participated in the Physician & Payer Forum, a group 
that presents physicians' prescribing habits, are expecting an increase in their use of 
antibiotic prophylaxis (preventive measure) to help avoid the development of hospital-
acquired infections (Decision Resources Inc., 2008). 
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Screenings for MRSA is an important surveillance system for hospitals. It aids in 
preventing disease transmission and helps save resources. Understanding the dynamics of 
MRSA carriage may assist physicians in selecting appropriate treatment, identifying 
interventions, and preventing transmission in the population. 
Better tracking of MRSA strains nationwide is needed to observe its spread. Different 
strain typing methods have been utilized over the years to track the spread and provide 
insight into its control. Australia, Denmark, The Netherlands, Canada and the United 
Kingdom have been tracking MRSA over the years. However, this practice has not been 
true for the US (Mc Dougal et al, 2003). As the prevalence of MRSA continues to 
increase along with its geographical diversity in colonization and infection rates, and as 
the number of available therapies decrease; health care providers should take notice of 
their local rates of resistance (Ezeanolue et al., 2008). According to the Clark County, 
Nevada 2005-2006 county-wide Antibiogram, which list the bacterial strains and 
commonly used antibiotics, there were 28,551 reported infections with S. aureus of 
which 58% were MRSA (SNHD Board Meeting Minutes, 2007). 
The isolates used in this study were collected from a large urban county, public 
hospital in Las Vegas, Nevada. It is a 545 bed, level one trauma center, teaching hospital 
that offers a wide variety of services unique to the area of Southern Nevada and 
neighboring states such as level I trauma center, burn care center, cardiac rehabilitation, 
hyperbaric chamber, and infusion clinic (UMC, 2009). 
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Purpose of Study 
The purpose of this retrospective study was to determine the prevalence of MRS A 
nasal colonization among adult patients admitted at this hospital. Further characterization 
of each isolate was also performed. This involved: 1) detection of the mecA gene which 
codes for resistance to beta-lactam antibiotics; 2) assessment of antimicrobial 
susceptibility patterns; and 3) determination of isolate strain types. This study further 
described and compared the characteristics of CA-MRSA isolates and HA-MRSA 
isolates. The data gathered from this study were compared to the NHANES nasal 
colonization study done by Gorwitz et al., (2008) and Tenover et al., (2008). The 
comparison was performed to give a description of MRSA nasal colonization between 
sampled patients compared to the general public. 
To compare the results of this study to the NHANES results two hypotheses were 
tested. The first hypothesis was: strains isolated from the screened patients will be 
predominantly USA 100, USA300, and USA 800 as seen in the nationwide nasal 
colonization study by NHANES as performed by Tenover et al. (2008). The second 
hypothesis was: isolates gathered from this study will display a greater association with 
elderly age (>60 years), Black and White ethnicity, and female gender as seen in the 
nationwide nasal colonization study by NHANES as performed by Gorwitz et al., (2008). 
The result of this study will give an insight about MRSA nasal colonization among 
patients screened at the hospital and describe the populations that are at higher risk for 
subsequent MRSA infection. Furthermore, the information can aid in disease surveillance 
and appropriate treatments selection for physicians. 
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CHAPTER 2 
MATERIALS AND METHODS 
Specimen Handling and Bacterial Isolates 
Clinical specimens were collected from newly admitted patients at the participating 
hospital from September 2008 through December 2008. Specimens were collected during 
a routine MRS A nasal screening on adult (18 years and older) patients who demonstrated 
a high risk for acquiring MRSA infection (e.g. dialysis patients, patients with moist tissue 
infections, all critical care admits, invasive devices in place on admission, known MRSA 
infection prior to admission). 
A total of 1206 MRSA nasal screen swabs were collected by hospital staff during the 
study period, using a sterile BD CultureSwab™ (BD Diagnostics, Sparks MD) inserted 
from both anterior nares, rotated for 5 seconds, and inserted into the swab transport 
container. Specimens were then transported to the hospital laboratory and innoculated 
onto MRSA ChromAgar (BD & Company, Sparks, MD). Inoculated plates were then 
incubated aerobically for 24 hours at at 33-37°C. Plates negative for MRSA were 
incubated an additional 24 hours. Smooth, mauve, moderately sized, convex colonies 
recovered from the MRSAChromAgar and coagulase (BD & Company, Sparks, MD) 
positive, were interpreted as MRSA isolates. Atypical mauve colonies were further 
evaluated. These isolates were subcultured to Tripticase™ 5% sheep blood (BD & 
Company, Sparks, MD), incubated for 18-24 hours at 33-37°C, and tested for coagulase 
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activity using coagulase and/or Protein A using Staphaurex (Fisher HealthCare, Houston, 
TX). A total of 119 were reported by the hospital as MRS A positive. Of these positive 
isolates, 100 met the criteria to be included in this study and were innoculated onto 5% 
Sheep Blood Agar (Teknova, Hollister, CA). The isolates were packaged and marked as a 
Category B Infectious Disease Substance and transported in a biohazard transport 
container to the Environmental Health Microbiology Laboratory at UNLV, Biosafety 
Level II (BSL-2). At the laboratory, the SBA plates were incubated for 18-24 hours at 33-
37°C. Isolates were then analyzed for strain typing, susceptibility testing, and presence of 
the mecA gene. All used supplies were disposed of according to the IBC protocol (see 
Appendix I) which followed proper universal precautions. 
Data Collection 
Detailed patients' information was collected at the time of admission in accordance 
with the hospital's admission policies. However, for this study the only patient 
demographics retrieved from the hospital's electronic database included age, gender, and 
ethnicity. A numerical accessioning scheme was used to identify samples. No direct 
identifier was released with this study to ensure patient's privacy. 
Identification and Antimicrobial Susceptibility Testing 
In vitro antimicrobial testing was performed on all methicillin-resistant S. aureus 
isolates using the Vitek II Compact system (bioMerieux, Hazelwood, MO). Isolates were 
subcultured for two consecutive days on SBA before testing. Isolate identification testing 
was performed along with susceptibility testing using the Vitek® 2 Compact ID/AST 
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system (bioMerieux, Durnham, NC). Susceptibilities to clindamycin, erythromycin, 
gentamicin, levofloxacin, linezolid, moxifloxacin, oxacillin, tetracycline, 
trimethoprim/sulfamethoxazole, vancomycin were determined. For isolate identification 
testing, a bacterial suspension of each isolate was prepared, at an optical density of 0.5-
0.63 McFarland standard with isolated colonies. Each suspension was loaded onto a 
cassette containing a Vitek 2 GP cards (bioMerieux, Durham, NC). For isolate 
susceptibility testing, 280ul of the 0.5-0.63 McFarland standard was transferred to a 
sterile saline solution and loaded onto a cassette containing Vitek 2 AST-GP66 cards 
(bioMerieux, Durham, NC). Once loaded, the cassette was placed into the Vitek II 
Compact and processed according to manufacturer's protocols. Results of the 
susceptibility profile were stored electronically in the system and evaluated. The 
reference strains S.aureus ATCC 43300 (oxacillin resistant) and S. aureus ATCC 25923 
(oxacillin susceptible) were used as controls (Roisin et ai, 2008). Isolates were classified 
as susceptible or resistant; intermediate results were considered resistant. In case of 
discrepancy, Vitek II identification and susceptibility testing were repeated. 
Detection of inducible clindamycin resistance was performed on all isolates that 
demonstrated erythromycin-resistance and clindamycin-susceptible. Erythromycin and 
clindamycin disks (Becton Dickinson, Sparks, MD) were placed 15-mm apart after 
innoculating a the Mueller Hinton agar plate (BBL Mueller Hinton II agar, BD 
Diagnostics) with a bacterial suspension of 0.5 McFarland standard (Hindler,. 2004). 
Flattening of the zone in the area between the disks indicates that the organism has 
inducible clindamycin resitance and is then reported as clindamycin resistant. The 
11 
reference strains S. aureus ATCC 25923 (no induction) and S. aureus ATCC BAA-977 
(clindamycin inducible) were used as controls. 
DNA Extraction and Purification 
DNA extractions were conducted using Mobio UltraClean™ Microbial DNA 
Isolation Kit (Mo Bio Laboratories, Carlsbad, CA). This product is designed to isolate 
bacterial DNA from microorganisms by lysing the microorganisms through the use of 
heat, detergent and mechanical force against specialized beads. After cell lysis, the DNA 
is then released onto a silica spin filter. The filter is then washed, and the DNA is 
recovered for further testing. 
A 10ul loop of plated culture was suspended in a MicroBead Solution containing salts 
and buffer which helps stabilize and homogeneously disperse the cells. A reagent 
containing sodium dodecylsulfate (SDS) and other disruption agents were then added to 
lyse the cells. The solution was vortexed which combines both chemical and mechanical 
lysis condition to release the nucleic acids from the cells. The culture suspension was 
then centrifuged to clear the solution of cell debris, leaving the DNA in the supernatant. 
A reagent was then added to remove contaminating organic and inroganic material. The 
culture supernatant was then loaded onto a spin filter device with a high salt concentrated 
reagent to help bind the DNA to the spin filter membrane allowing other contaminants to 
pass through the filter. An ethanol-based washed solution was then used to further clean 
the filter bound DNA. The filter was then centrifuged to dry and remove any remaining 
wash solution. The filter was washed with an elution buffer to aid in DNA release. The 
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DNA was recovered in a 35ug DNA-free Tris buffer and quantitated using a UV 
spectophotometer (Thermo Fisher Scientific Inc., Pittsburgh, PA). 
Automated rep-PCR DNA Fingerprinting 
Isolates identified as S. aureus with an oxacillin-resistant profile from the antibiotic 
susceptibility testing were subjected to strain typing using the DiversiLab (bioMerieux, 
Athens, GA) according to manufacturer's protocol. Isolates were re-streaked onto SBA 
and incubated overnight as described above. DNA was extracted using the DiversiLab 
Staphylococcus Fingerprinting kit (Bacterial BarCodes Inc., Athens, GA). The 
GeneAmp® PCR System 2400 (Applied Biosystems, Foster City, CA) was used for PCR 
analysis. The materials for amplification included: rep-PCR MM1, GeneAmp 10X PCR 
Buffer, Primer Mix, AmpliTaq® DNA Polymerase and DNA tempalate. The thermal 
cycling parameters were initial denaturation of 2 minutes at 94°C, 35 cycles of 94 °C for 
30 seconds for denaturation, annealing at 45 °C for 30 seconds, extension at 70 °C for 90 
seconds and a final extension at 70 °C for 3 minutes. 
The resulting DNA was loaded onto the DiversiLab Caliper® LabChip device 
(Bacterial BarCodes, Inc., Athens, GA) and processed according to manufacturer's 
protocols. The DiversiLab chip is first loaded with a gel-dye mix followed by the DNA 
Marker and the resulting DNA rep-PCR product. Comparisons of strain profiles were 
made of isolates from this study and isolates in the Biomerieux database. The Diversilab 
software was used to analyze results using Pearson correlation coefficient to determine 
the distance matrices and the weighted-pair group method with arithmetic mean to create 
the dendograms (Healy et al., 2005). The software reports includes the dendogram, 
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similarity matrix, electropherograms, virtual gel images, scatter plots and demographic 
fields. Isolates were grouped according to the closests match from the Biomerieux 
database's top matches showing > 90% similarity . Additional review of the virtual gel 
images, graph overlays and similarity matrix were performed for samples showing 
similarities to two different strain types. 
mecA Gene Assay 
Resistance to oxacillin was confirmed by detecting the mecA gene. A real-time PCR 
assay applying the TaqMan® (Applied Biosystems, Foster City, CA) technology was 
used to detect the mecA gene (Francois et al., 2003). PCR analysis was performed using 
the 7900HT Fast Real-Time PCR System (Applied Biosystems) using the following 
mecA primers sequence (5'-3'): forward, CAATTGATCGCAACGTTCAATTT and 
reverse, AGGTCCTTACGTCTTTCTGGT. Primers were acquired from Operon 
Technologies (Huntsville, AL). The TaqMan® probe sequence was 6-FAM 
TGGAAGTTAGATTGGGATCATAGCGTCAT-TAMRA (Applied Biosystems, Foster 
City, CA). 
The materials for the amplification were IX TaqMan® Universal Primer Mix 
(Applied Biosystems), 100 nM of each forward & reverse primers, 75 nM probe, and 
genomic DNA template. A volume of 25 ul nuclease-free water (Promega Corp., 
Madison, WI) was used to adjust the reaction volume. The parameters for thermal cycling 
were run on standard mode of 2 minutes at 50°C, 10 minutes at 95 °C, and 40 cycles of 15 
seconds at 95°C then 1 min at 60 °C. The reference strain S. aureus ATCC 43300 (mecA 
gene positive) and S. aureus ATCC 25923 (mecA gene negative) were used as controls. 
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Statistical Analysis 
To summarize the patients' characteristics and the prevalence of MRSA descriptive 
statistics were used. Statistical examination of organism characteristics, as determined by 
laboratory testing, was performed using SPSS (15.0 software) and Microsoft office excel 
2003. Data are shown as a raw number or percentage of each group. Categorical data 
were compared using chi-square test or Fisher's exact test when the categorical variable 
cells were <5. A p value of less than 0.05 was considered significant. 
IRB Approval 
A separate IRB approval was requested and granted from each institution (the 
hospital and UNLV). UNLV Institutional Review Board approved as exempt (90PRS # 
0807-2811, August 7, 2008). The hospital's Institutional Review Board request was also 
approved as exempt (UMC-IRB00002394, August 2, 2008) for this project. UNLV's 
Institutional Biosafety Committee (IBC) approval was also obtained prior to initiation of 
this research. 
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CHAPTER 3 
RESULTS 
MRSA Nasal Colonization Prevalence among Hospital Isolates 
Within the four-month study period, 119 out of 1206 samples were reported by the 
hospital as MRSA-positive. The prevalence of MRSA nasal colonization among all 
samples collected at the hospital was 9.87% during the study period. Out of all the 
positive isolates, 100 met the criteria to be included in this study. 
Table 1. Demographic characteristics of the 100 samples with methicillin-resistant 
Staphylococcus aureus colonization. 
Patient Hospital isolates 
characteristics n=100 
Gender 
Male 69 
Female 31 
Ethnicity 
Whites 64 
Blacks 17 
Spanish 15 
Other 4 
Age group 
18-34 7 
35-59 51 
>60 42 
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Patient Demographics among Hospital Isolates 
Of the 100 isolates collected for this study, 69% were from male patients, while 31% 
were from female patients (Table 1, Figure 1). The mean patient age was 58 years (range, 
18 to 92). Sixty-four percent of the samples were from patients with White ethnic 
background, followed by Black at 17%, Spanish at 15% and other ethnic backgrounds at 
4% (Table 1, Figure 2). Eight percent of the samples were collected from patients 18 to 
34 years, 50% were from patients 35 to 59 years, 42% were from patients 65 years or 
older (Table 1, Figure 3). 
Strain Type Distributions among Hospital Isolates 
The hospital MRSA isolates showed a significant difference in proportion between 
HA-MRSA and CA-MRSA strain types (p < 0.001). The most common strain type seen 
among hospital MRSA isolates was USA 100 which was present in 35% out of the 100 
isolates tested. The second most common strain type was USA300, present in 25% of all 
the isolates. The Brazilian and the Iberian were the third and fourth most common strain 
type isolated at 16% and 14% respectively. 
Patient Demographic and Strain Type Distribution among Hospital Isolates 
The most common strain type seen among study isolates was USA 100 which was 
mainly collected from patients who were white, male, and 60 years or older (Table 4-6). 
The second most common strain type was USA300. These isolates were mostly collected 
from patients who were white, male, and 35 to 59 years of age (Tables 4-6). The third 
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most common strain type was Brazilian. Isolates that belong in this group were collected 
from patients who were male, white, and between the ages of 35 to 59 years (Tables 4-6). 
No statistically significant association was found between patient ethnicity and 
MRSA stain type (p = 0.544). Patient gender and MRSA strain type also did not show a 
statistically significant association (p - 0.335). However, a statistically significant 
association was seen between patients' age group and MRSA strain type (p = 0.02). Over 
65% of USA 100 were from older patients age 60 years or over. However, over 75% of 
US A3 00 were from patients aged 35 to 59 years. 
HA-MRSA and CA-MRSA Comparison among Hospital Isolates 
Strain Type and Antimicrobial Susceptibilities Testing among Hospital Isolates 
HA-MRSA strains (USA 100, USA200, USA500, USA600, USA700, USA800, 
Iberian, and Brazilian) accounted for 73% of the isolates among hospital samples (Table 
3). CA-MRSA (USA300, USA400, USA 1000, and USA 1100) accounted for 27% of the 
isolates (Table 3). 
USA100 was the most predominant strain type among HA-MRSA hospital isolates. It 
was highly susceptible (greater than 75%) to gentamicin, quinipristin/dalfopristin, 
linezolid, tetracycline, rifampin, vancomycin and trimethoprim/sulfamethoxazole. 
However, USA100 showed to be less susceptible (less than 50%) to levofloxacin, 
clindamycin, and erythromycin. 
USA300 was the most predominant among CA-MRSA isolates. It was highly 
susceptible to gentamicin, quinipristin/dalfopristin, linezolid, tetracycline, rifampin, 
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vancomycin and trimethoprim/sulfamethoxazole, clindamycin. It was less susceptible to 
levofloxacin and erythromycin. 
Antimicrobial Susceptibility Testing among Hospital Isolates 
All of the hospital isolates tested positive for the mecA gene which codes for 
methicillin resistance. None of the isolates were susceptible to penicillin and oxacillin. 
All of the study isolates were susceptible to vancomycin, quinipristin/dalfoprinstin, and 
linezolid. The CA-MRSA and HA-MRSA isolates showed a significant difference in 
antibiotic susceptibility proportion (p < 0.001). CA-MRSA was susceptible to more 
antimicrobial agents than the HA-MRSA (Table 8). 
HA-MRSA and CA-MRSA antimicrobial susceptibility results indicate a high 
susceptibility to rifampin (98.6% vs. 100%; p = 0.308). Although there was a statically 
significant difference in proportion for gentamicin (80.8% vs. 96.3%; p = 0.008), 
tertracycline (78.1% vs. 96.3%; p = 0.002), and trimethoprim/sulfamethaxazole (78.1% 
vs. 96.3%; p = 0.002); both HA-MRSA and CA-MRSA groups indicate a high 
susceptibility to the antimicrobial agents mentioned. There was a statistically significant 
difference in susceptibility proportions between HA-MRSA and CA-MRSA for 
levofloxacin (4.2% vs. 22.2%; p < 0.001) and erythromycin (8.3% vs. 18.5%; p = 0.21), 
but MRSA was still less susceptible to levofloxacin and erythromicin in both groups. 
Susceptibility to clindamycin (36.9% vs. 81.5%; p < 0.001) was less susceptible among 
HA-MRSA than CA-MRSA and this difference was statistically significant. 
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Table 2. PFGE designation for methicillin-resistant S. aureus hospital-associated (HA-
MRSA) and community-associated (CA-MRSA) grouped according to USA and 
European class. 
MRSA Pulse-Field Gel Electrophoresis Designation 
HA-MRSA CA-MRSA 
USA 100 USA300 
USA200 USA400 
USA500 USA1000 
USA600 USA 1100 
USA700 
USA800 
Iberian 
Brazilian 
Note. Table was composed from PFGE designation as reported from studies by Klevens 
et al., (2007); Buck et al., (2005); McDougal et al, (2003) and Bartels et al., (2007). 
Table 3. Hospital-associated methicillin-resistant S. aureus (HA-MRSA) and community 
associated MRSA (CA-MRSA) class distribution among hospital isolates. 
MRSA Class No. of isolates Percentage 
HA-MRSA (n=73) 
USA100 35 47.9 
USA200 1 1.3 
USA700 6 8.2 
USA800 1 1.3 
Iberian 14 19.2 
Brazilian 16 21.9 
CA-MRSA (n=27) 
USA300 25 92.6 
USA1000 1 3.7 
USA1100 1 3.7 
Note. G2=<0.001; p=<0.001 for HA-MRSA and CA-MRSA comparison. 
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The susceptibility patterns for each strain type belonging to CA-MRSA and HA-
MRSA groups generally followed a similar pattern with the exception of the Brazilian 
clone. The Brazilian isolates were less susceptible to more antibiotics than other 
HA-MRSA isolates, especially to trimethoprim/sulfamethoxazole, gentamicin, and 
tetracycline (Table 7). 
Hospital and NHANES Isolate Comparison 
Hospital and NHANES Isolate Strain Type Comparison 
USA100 was the most common strain type seen among this study's hospital MRSA 
isolates. This strain was present in 35% of the 100 isolates tested (Table 8). The second 
most common strain type was USA300, present in 25% of all the isolates. The most 
common strain type isolated among NHANES MRSA isolate was USA100, with 44.8% 
of the 134 isolates tested. This was then followed by USA300 and USA800, each present 
in 17.1% of all the isolates tested. 
Hospital and NHANES Isolate Antimicrobial Susceptibility Comparison 
None of the isolates were susceptible to penicillin and oxacillin. All of the sample and 
NHANES isolates were highly susceptible to vancomycin, rifampin, gentamicin, 
tetracycline, quinipristin/dalfoprinstin, trimethoprim/sulfamethoxazole, and linezolid 
(Tenover et ah, 2008) (Table 9). Study isolates showed less susceptibility to levofloxacin 
than NHANES isolates. Both groups were less susceptible to erythromycin. 
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Table 8. Susceptibility pattern for community-associated (CA-MRSA) and hospital-
associated (HA-MRSA) types among hospital isolates. 
Percentage of isolates for indicated 
MRSA type 
Antimicrobial Agent p value 
HA% CA% 
GM 
LE 
E 
CC b 
QDA 
LZ 
TET 
RIF 
SXT 
VA 
80.8 
4.2 
8.3 
36.9 
100 
100 
78.1 
98.6 
78.1 
100 
96.3 
22.2 
18.5 
81.5 
100 
100 
96.3 
100 
96.3 
100 
0.008 
<0.001a 
0.21 
O.001 
NT 
NT 
0.0026 
0.3086 
0.002 
NT 
Note. GM=Gentamicin, LE=levofloxacin, ER=erythromycin, CC=Clindamycin, 
QDA=Quinipristin/Dalfopristin, LZD=Linezolid, VA=Vancomycin, TET=Tetracycline, 
RIF=Rifampin, SXT= Trimethoprim/Sulfamethoxazole. 
G2=<0.001; p=<0.001 for comparison between HA-MRSA & CA-MRSA. 
a
 Fisher's exact test. 
b
 Susceptibility due to inducible and constitutive resistance. 
Values are the same, no test of comparison performed. 
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Table 9. Distribution of strain types of study isolates and NHANES 2001-2004. 
Strain type 
USA 100 
USA200 
USA300 
USA400 
USA600 
USA700 
USA800 
USA 1000 
USA1100 
IBERIAN 
BRAZILIAN 
Study 
n=100 
35 
1 
25 
0 
0 
6 
1 
1 
1 
14 
16 
Study 
Percentage 
35 
1 
25 
0 
0 
6 
1 
1 
1 
14 
16 
NHANES a 
n=134 
60 
6 
23 
8 
3 
3 
23 
1 
1 
0 
NR 
NHANES 
Percentage 
44.7 
4.4 
14.1 
5.9 
2.2 
2.2 
17.2 
0.7 
0.7 
0 
NR 
Note. NR represents values that were not reported. 
a
 These value do not include six isolates, each with unique PFGE pattern. 
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Table 10. Susceptibility profile for MRSA study isolates and NHANES isolates. 
Antimicrobial ^otoe* Hospital Isolate NHANESc NHANES 
agent
 = „ . Percentage n=133 Percentage 
PCG 
oxs 
GM 
LE 
E 
CC a 
QDA 
LZD 
VA 
TET 
RIF 
SXT 
Note. PEN= 
0 
0 
85 
9 
11 
46 
100 
96 
100 
83 
99 
83 
=Penicillin, OX= 
0 
0 
85 
9 
11 
46 
100 
96 
100 
83 
99 
83 
Oxacillin GM=Gentamicin, 
0 
0 
132 
60 
24 
50 
133 
133 
133 
122 
131 
133 
LE=levofloxacin, 
0 
0 
99.3 
45.1 
18.1 
37.6 
100 
100 
100 
91.7 
98.5 
100 
E=erythromycin, CC=Clindamycin, QDA=Quinipristin/Dalfopristin, LZD=Linezolid, 
VA=Vancomycin, TET=Tetracycline, RIF=Rifampin, 
SXT= Trimethoprim/Sulfamethoxazole. 
a
 Susceptibility due to inducible and constitutive resistance. 
b
 These values do not include the 16 Brazilian clones. Comparisons were made only on 
strain types reported by both studies. 
c
 These values do not include six isolates, each with unique PFGE pattern. 
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CHAPTER 4 
DISCUSSION 
The strong association between S. aureus carriage and risk factors for subsequent 
infections has led numerous researchers to examine the presence of S. aureus nasal 
colonization and project subsequent infections. The rising prevalence of MRSA 
colonization has several implications for public health and also for clinical diagnosis and 
treatment of patients (Jung et al, 2006). This retrospective study determined the 
prevalence of MRSA nasal colonization and described the characteristics of CA-MRSA 
and HA-MRSA isolates from nasal cultures collected from adult patients screened upon 
admission at the participating Las Vegas community hospital. Patient isolates were taken 
from routine nasal screens collected from September 2008 through December 2008. The 
result of this study will give an insight in the characterization MRSA and the prevalence 
of MRSA nasal colonization among adult patients at high risk for subsequent infection in 
the Las Vegas community. 
HA-MRSA and CA-MRSA Comparison among Hospital Study Isolates 
The characterization between CA-MRSA and HA-MRSA used for this study was 
performed based on predominant strain type seen in each group as previously reported by 
Klevens et al. (2007), Mc Dougal et al. (2003), Battel et al. (2007) Buck et al., (2005), 
and Bartels et al. (2007). This study demonstrated that there is a higher proportion of HA-
MRSA nasal colonization among sampled patients (73%) compared to CA-MRSA 
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(27%). The CA-MRSA nasal colonization isolates were susceptible to more antimicrobial 
agents than the HA-MRSA. This result was also consistent with previous MRSA studies 
as mentioned earlier. 
There was also a higher percentage of the EMRSA strain type (e. g. Iberian and 
Brazilian clones) isolated among MRSA colonized patients from this study compared to 
the NHANES. This suggests that new clones of MRSA are being introduced or currently 
exist in the study population. Data from the susceptibility testing suggest that 14 of the 
Iberian strains isolated follow the same antimicrobial susceptibility pattern as other HA-
MRSA. The 16 Brazilian isolates were less susceptible to more antibiotics than the other 
HA-MRSA isolates, especially to trimethoprim/sulfamethoxazole, gentamicin, and 
tetracycline. 
Hospital and NHANES Isolate Comparison 
The most common strain types seen in this study were strain types USA 100 (35%) 
and USA300 (27%). These findings are consistent with the NHANES study, which 
showed a high prevalence of USA 100 (44%) and USA300 (17.1%), in addition to 
USA800(17.1%). 
Colonization of MRSA was more common among white, males, and aged 50 to 64 
years. The NHANES study showed a higher prevalence of MRSA colonization among 
females and individuals aged 60 years and older. Black and White ethnicity showed an 
equally high prevalence rate. 
The similarity seen between the common strain types observed in both population 
shows that both USA 100 and USA300 are prominent in both populations. The high 
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proportion of USA800, which is frequently associated with pediatric patients, was 
probably due to the proportion of pediatric patients included with the NHANES study. 
The difference in the demographic distribution of MRS A nasal colonization between 
the two groups suggests that the sampled population is different from NHANES. The 
sampled population does not represent the general public but a subset in the Las Vegas 
community. The NHANES data were used for comparison as it was the largest study 
performed on the subject of nasal colonization in the US. The data from this nationwide 
study were used as the best assumption to represent the general public. Nevertheless, the 
data gathered from this study could be used as a guide to aid in MRSA surveillance, 
identify interventions and guide physicians in selecting appropriate treatments. 
Strain Type Analysis 
The most predominant strain type isolated from nasal cultures was USA 100, also 
known as New York/Tokyo clone. It has been the most common stain type found among 
health-care associated infections in the US (Mc Dougal et al, 2003). In a 2005 
population-based surveillance for invasive MRSA, USA 100 was the most common strain 
type seen among invasive health-care onset MRSA infections (Klevens et al, 2007). 
The second most common strain type isolated from nasal cultures was USA 300. It is 
the strain most often isolated in MRSA community outbreaks. It frequently harbors the 
Panton-Valentine leukocidin. This toxin has been highly linked as an epidemiological 
marker for CA-MRSA strains. While PVL is a useful marker for strains with the 
capability to cause severe S. aureus infections, its clinical implication has yet to be 
determined (Voyich et al, 2006). 
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Mc Dougal et al, (2003) describe the first eight lineages of USA MRSA clones from a 
previous study, USA 100 to USA800. USA800 clones have been found to belong in the 
same cluster as other MRSA belonging in the pandemic pediatric clone. USA200 is the 
second most common healthcare-associated US isolate. USA 400 is associated with 
community onset infections along with USA1000 and USA1100 (Klevens et al, 2007). 
USA 500, USA 600, and USA800 have been associated with healthcare-associated 
MRSA. USA700 has been emerging in both community and healthcare settings 
(McDougal et al, 2003). 
International hospital clones of MRSA are known as EMRSA. These epidemic clones 
are named either by the place where they were first found or by some unique 
epidemiological property (Oliveira et al, 2002; Barrels et al, 2008). The Iberian clone 
has been found in several countries in Europe and the Brazilian clone has been reported 
to be predominant in Portugal (Stefani & Varaldo, 2003). 
Antimicrobial Susceptibility 
The antibiotics used for this study were efficacious against bacteria through different 
mechanisms. Penicillins, cephalosporins, and carbapenems belong in the family of 
antibiotics called beta-lactams. These antibiotics work by disrupting the synthesis of the 
cell envelope in growing cells, inactivating the penicillin-binding proteins thus inhibiting 
the synthesis of bacterial cell wall. These antibiotics are considered bactericidal, only 
growing cells are killed (Singleton, 1992). However, shortly after the introduction of 
penicillin, bacterial strains developed resistance to beta-lactamases. Therefore, the 
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development of semi-synthetic penicillin (e.g. methicillin and oxacillin) was used as a 
replacement for penicillin. 
Antibiotics such as gentamicin, tetracycline, erythromycin, clindamycin, linezolid, 
and quinupristin-dalfopristin work by inhibiting protein synthesis in bacteria (Salyers & 
Whitt, 2005). Rifampin belongs with the family of antibiotics which prevents prevent 
bacterial growth by inhibiting the RNA polymerase, halting the bacteria protein synthesis 
(Gladwin & Trattler, 2004). Levofloxacin works by inhibiting the enzyme DNA gyrase, 
resulting in the breakage of bacterial DNA structure and inhibition of DNA synthesis 
(Gladwin & Trattler, 2004). Vancomycin works much like penicillin as it inhibits the 
synthesis of bacterial cell wall. Another commonly prescribed antibiotic against MRS A is 
trimethoprim/sulfamethoxazole. This antibiotic inhibits the necessary cofactors for 
bacterial DNA synthesis (Salyer & Whitt, 2005; Gladwin & Trattler, 2004). 
This study demonstrated that study isolates were less susceptible than NHANES 
isolates, but the over all susceptibility pattern followed a consistent pattern. An apparent 
difference in susceptibility was seen with levofloxacin. Its susceptibility was substantially 
less than that of NHANES. This could mean that levofloxacin is losing its effectiveness 
in both population of high risk patients for MRSA infection and the general public. 
Automated Methods 
Pulse-field gel electrophoresis (PFGE) is a highly discriminatory tool and is 
considered as the "gold standard" genotyping method (Healy et ah, 2005) However, 
PFGE is complicated, labor intensive and can produce inconsistent results. For this study, 
a new automated and commercially adapted repetitive sequence-based PCR (rep-PCR) 
35 
genotyping method was used (DiversiLab system). According to a comparison study 
performed by Reece et al. (2005) and Healey et al. (2005) rep-PCR results were stable, 
reproducible, and highly concordant with PFGE. The DiversiLab system also offers 
efficiency, excellent discriminatory power, and reproducibility to allow database building 
and offers result comparison with other institutions. 
To determine the oxacillin resistance of each isolate, numerous methods were 
performed for verification. First, the isolates were inoculated onto CHROM™ agar, 
which is selective for MRSA growth. Second, the isolates were susceptibility tested using 
the Vitek 2. Lastly, the detection of mecA gene, which codes for methicillin resistance, 
was detected using a reference method PCR assay. 
Antibiotic-sensitivity testing is used to determine the susceptibility of a pathogen to a 
range of antibiotics. These results can aid clinicians to select appropriate antibiotic 
therapy. One common form of this test is the disk diffusion method. This process 
normally requires a day of incubation. For this study, an automated antimicrobial 
susceptibility testing system (Vitek 2) was used. According to a study by Roisin et al. 
(2008) the Vitek 2 was as accurate as the disk diffusion method. 
Disease Transmission and Prevention 
The increasing prevalence of MRSA infection in the community and healthcare 
setting continues to be a major public health concern. The association between MRSA 
carriage and subsequent infection requires further study. Although the prevalence of 
colonization in the general public remains low, further study is needed to track changes 
and indicate ongoing trends (Gorwitz et al, 2008). The low prevalence of MRSA 
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colonization in the general population does not currently warrant surveillance for 
individuals not at high risk for MRSA infection (Gorwitz et al, 2008) 
The high prevalence of nasal colonization and the increased risk for subsequent 
MRSA infection among hospital patients suggests continued monitoring of MRSA 
colonization in patients. Screenings for MRSA is an important surveillance system for 
hospitals. It aids in preventing disease transmission and helps save resources. Patients 
that are infected or colonized with MRSA are the most important reservoir of MRSA 
(Siegel et al, 2006). The practice of active surveillance in hospitals can help reduce 
MRSA infections and related complications. This practice should involve a constituency 
of departments, including physicians, nurses, infection control, senior hospital personnel, 
environmental services purchasing and finance (Uettwiller-Geiger, 2008). Hospital 
personnel can also serve as reservoirs for MRSA, possibly harboring the organism for 
months (Siegel et al, 2006). Contact and standard precautions should also be used for 
individuals that have contact with patients. The application of new technology should 
also be utilized to aid in surveillance and identification of MRSA along with other 
multiple drug resistant organisms. 
New antibiotics are being created to be used against MRSA, although development of 
new antibiotics has not been promising as an answer to the antibiotic resistance problem. 
It is estimated that it costs over $800 million and requires 10 to 15 years to take a new 
antibiotic from conception to approval (Salyer & Whitt, 2005). Alternate drug therapies 
and combination of drug therapies should also be considered. 
The public, especially individuals that are at an increase risk for acquiring MRSA in 
the community, should be educated about MRSA disease transmission and prevention. 
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This includes taking medications as directed, keeping lesions covered with clean and dry 
bandages, practicing good hand hygiene, and avoiding the sharing of contaminated items 
such as towels and razors (Moran et al, 2006). 
Limitations of Study 
This study was cross sectional in design and only accounted for point prevalence of 
nasal colonization among participants. No subsequent cultures were collected and no 
follow-up study was performed on identified MRSA colonized patients. The study 
hospital was a public hospital; therefore, a more underserved population at high risk for 
MRSA may have been included in the study. No patient identifiers were collected so 
duplication of samples may have occurred. The number of patients that declined testing 
was also not collected. Characterization between CA-MRSA and HA-MRSA was 
performed based on predominant strain type seen in each population from previous 
studies. Additional patient medical history and other genetic marker could help further 
characterize the isolates into HA-MRSA or CA-MRSA category. Due to limited time and 
resources, the test for Panton-Valentine leukocidin gene (usually contained among CA-
MRSA) was not performed. 
The higher prevalence of MRSA colonization among the hospital study population 
may be due to the difference in risk acquisition for MRSA. Samples used in this study 
were from adult patients screened upon hospital admission who demonstrate a high risk 
for acquiring MRSA (i.e. dialysis patients, patients with moist tissue infections, all 
critical care admissions, invasive devices in place on admission, known MRSA infection 
prior to admission). Conversely, NHANES samples were collected from non-
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institutionalized patients (i.e. not in hospitals, long-term care facilities, or prisons). The 
sampled population does not represent the national population. Nevertheless, the data 
gathered from this study could be used as a guide to aid in counseling physicians in 
selecting appropriate treatments, and prevent transmission and identify interventions. 
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CHAPTER 5 
CONCLUSION 
The aim of this study was to determine the prevalence of MRSA nasal colonization 
among adult patients admitted at a Las Vegas community hospital and further 
characterize each MRSA isolate. The information gathered from this study was then 
compared to the NHANES nasal colonization study. 
This study showed that the predominant strain types isolated among study isolates 
were predominantly USA100 and USA300. There also was a high percentage of EMRSA 
strain sub types (Iberian and Brazilian clones) present among the hospital isolates. This 
result refutes the first hypothesis that the sample isolates will also show a predominance 
of USA 100, USA300 and USA800 like the NHANES study. 
Data from the susceptibility testing of study isolates suggest that 14 of the Iberian 
strains follow the same antimicrobial susceptibility pattern as other isolates in the HA-
MRSA group. However, the 16 Brazilian isolates were less susceptible to more 
antibiotics than the other HA-MRSA isolates, especially to gentamicin, 
trimethoprim/sulfamethoxazole, and tetracycline. This suggests that new clones of 
MRSA are being introduced or currently exist in the study population. 
The data from this study showed that the hospital study population had a higher 
prevalence of nasal colonization than NHANES. Among the hospital study population, 
patients that were white, male, and aged 35 to 59 years of age were more associated to 
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being colonized by MRSA. These groups are also at an increased risk for subsequent 
MRSA infection. The findings from this study and NHANES both described the older 
population to be more colonized, compared to younger age. However, colonization was 
more associated among the black and white race and females gender in the NHANES 
study which was not similar to the hospital study population as initially hypothesized. 
The high prevalence of USA 100 and US A3 00 strain types are consistent in both the 
study isolates and NHANES, suggesting that both strains are prominent in both 
populations. The high prevalence of USA800 in the NHANES study was probably due to 
the pediatric patients included in their study. Conversely, the hospital study only included 
adult patients. 
Data from the antimicrobial susceptibility testing demonstrated that the hospital 
isolates were less susceptible to the antimicrobial agents tested than NHANES isolates. 
Nonetheless, over all susceptibility patterns follow a consistent pattern. An apparent 
difference in susceptibility was seen with levofloxacin. Study isolates were substantially 
less susceptible to levofloxacin than NHANES. This could suggest that levofloxacin is 
losing its effectiveness more rapidly among colonized patients than colonized individuals 
in the general public. 
The difference in the demographic distribution of MRSA nasal colonization between 
hospital patients and NHANES patients suggests that the sampled population is different 
from NHANES. The sampled population does not represent the general public. 
Nevertheless, the data gathered from this study could be used as a guide to aid to in 
counseling physicians in selecting appropriate treatment, preventing transmission and 
identifying possible interventions. 
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Continued active surveillance, contact and standard precautions practice can help 
prevent the spread of MRS A colonization and infection in hospitals and other healthcare 
facilities. The application of new technology should also be utilized to aid in surveillance 
and identification of MRSA along with other multiple drug-resistant organisms. 
Healthcare providers should be aware of their local rate of resistance to different 
antimicrobial agents as the prevalence of MRSA continues to increase and evolve 
(Ezeanolue et al, 2008). Additionally, the public, especially individuals that are at an 
increase risk for acquiring MRSA in the community, should be educated about MRSA 
disease transmission and prevention. 
Performing prevalence studies assists in examining the relationship between specific 
diseases and health-related factors as they exist in individuals in a population at a 
particular time. Increased assessment of the population dynamics of MRSA carriage may 
assist in determining the extent of its prevalence. Further study is needed to track changes 
and observe trends of MRSA colonization and MRSA infections in the Southern Nevada. 
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APPENDIX I 
UNIVERSITY OF NEVADA LAS VEGAS BSL-2 LABORATORY 
STANDARD OPERATING PROCEDURES (SOPS) 
This SOP document should include specific information for the laboratories and 
procedures being performed. It is meant to give details in addition to UNLV's adopted* 
standard BSL-2 procedures (pages - ) and Exposure Control Plan (available through 
rms.unlv.edu). 
All faculty, staff and students should familiarize themselves with these procedures and 
sign page prior to starting work in this BSL-2 laboratory. Questions should be directed to 
the Principal Investigator. A copy of the SOP must be forwarded to the UNLV Biosafety 
Officers and a copy must be retained in the laboratory's Biosafety Manual. 
Principal Investigator: Linda Stetzenbach, Ph.D. 
BSL-2 Room Number: MPA-231 
Biohazards being used: (MSDS attached if available) 
Description of Procedures(s): 
Speciment Collection: 
Clinical specimens will be collected from September 2008 until January 2009 from 
adult (18 years and older) emergency department patients admitted to the University 
Medical Center (UMC), Las Vegas, NV. An expected sample size of 200 to 300 is 
anticipated over the study time period. Methicillin-resistant Staphylococcus aureus 
(MRSA) positive isolates will be inoculated onto agar slants. Agar slants will be 
packaged and marked as a Category B Infectious Disease Substance. They will be 
transported in a biohazard transport container to Dr. Stetzenbach's UNLV Biosafety 
Level II (BSL-2) laboratory for strain typing and susceptibility testing. All used supplies 
will be disposed of according to the IBC protocol which will follow proper universal 
precautions. 
Isolation of MRSA: 
Isolates will be streaked to 5% Sheep Blood Agar and incubated for 18 - 24 hours at 
35°C. A suspension of each isolate, at an optical density of 0.5-0.63 McFarland standard, 
will be loaded onto a cassette containing a AST cards. Once loaded the cassette will be 
placed into the in the Vitek II Compact and processed according to manufacturer's 
protocols. Results of the susceptibility profile will be stored electronically in the system 
and evaluated. 
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MRSA Strain Typing: 
Isolates identified with an Oxacillin-resistant profile from the antibiotic susceptibility 
testing will be subjected to strain typing using the DiversiLab (Biomerieux) according to 
manufacturer's protocol. All manipulations of colonies for strain typing will be 
manipulated in the BSL-2 biosafety cabinet located in MPE 231. Isolates will be re-
streaked onto 5% Sheep Blood Agar and incubated overnight as described above. DNA 
extraction will be conducted using Mobio UltraClean™ Microbial DNA Isolation Kit 
(Carlsbad, CA). Once the DNA is extracted the remaining protocol will be conducted in 
the laboatory as the material no longer is a risk for infection. The GeneAmp ® PCR 
System 2400 (Applied Biosystems, Foster City, CA) will be used for PCR analysis. The 
resulting DNA will be loaded onto the DiversiLab chip and processed according to 
manufacturer's protocols. Comparisons of strain profiles will be made of isolates from 
this study and isolates in the Biomerieux database. 
Hazards: The following materials and/or equipment associated with this procedure may 
present exposure hazards, health hazards, and/or physical hazard. Identify potential 
exposures that may occur during sample preparation, and/or experimental manipulation 
(i.e., use of sharps, aerosol generation during centrifuge, mixing or sonication, etc): 
No sharps will be used during this project. Risk of aerosolization during 
manipulation is minimal due to the closed screw cap. However, following vortexing the 
vials will only be opened under the BSL-2 biological safety cabinet located in MPE 231. 
Small biohazard bags will be used for the disposal of contaminated pipette tips and 
swabs. When finished, the small biohazard bag will be taped shut. Inoculated Petri 
plates must also be taped shut at the 6 and 12 o'clock position. All agar plates, vials, 
swabs, pipettes and pipette tips, and identification and AST cards will be autoclaved prior 
to disposal. 
Administration Controls: The following administrative controls are in place to avoid 
exposures (i.e., training, signage, restricted entry, etc): 
All personnel manipulating the swab samples, bacterial isolates, exposed agar plates, 
and contaminated materials before autoclaving have been trained by the Principle 
Investigator and will have undergone UNLV Risk Management blood-borne pathogens 
and BSL-2 training prior to the initiating of sample collection for this project. While 
personnel in the adjoining School of Public Health Environmental Health Laboratory 
have access to the shared anteroom of MPE 231, these individuals will be trained not to 
open the incubators belonging to the Emerging Disease Laboratory that are located in the 
shared space. These incubators are labeled with the biohazard symbol and verbage of 
biological hazards, and labeled with verbage of authorized personnel only. The shared 
refrigerator and ultra freezer in the anteroom will not be used for storage of infectious 
biological materials. Discarded potentially infectious material (e.g., exposed swabs, 
pipettes, incubated agar plates) will be disposed of into autoclave bags and autoclaved 
when the bags are <3/4 filled. 
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Engineering Controls: The following safety equipment must be used when carrying out 
these procedures, (i.e., chemical fume hood, biological safety cabinet, sealed centrifuged 
rotors, etc): 
Laboratory coats and eye protection will be worn by all personnel when potentially 
infectious materials are being manipulated in the MPE 231. The laboratory coats are 
cloth and will be laundered as necessary by a commercial company recommended by 
UNLV Risk Management. Additionally, disposable Tyvek arm sleeves will be worn by 
individuals manipulating MRSA cultures. Protective latex or non-latex gloves will be 
worn during manipulations of any exposed agar plates, isolates, inoculated suspensions, 
exposed swabs, and discarded materials prior to autoclaving, and during any 
manipulations involving DNA extraction, typing, or susceptibility testing. 
Additional Special Handling Procedures: Including any transport between labs or 
buildings (i.e., secondary containment): 
MRSA isolates will be transported from UMC hospital to UNLV MPE 231. All 
primary culture tubes will be individually labeled according to their contents and 
screwcaps will be Para filmed. The primary tube will be placed inside a sealable bag that 
has a biohazard symbol on it with an absorbent packing material. The secondary bag will 
be placed in a rigid sturdy outer container with a lid. This rigid container will then be 
placed inside an insulated cooler that has a lid that snaps that prevents it from opening. 
Leak proof ice packs will be placed inside the cooler. A DOT Class 6.2 Infectious 
Substance and Biohazard label will be placed on the outside of the cooler. A bill of 
lading, Material Safety Data Sheet and an emergency contact sheet which includes the 
School of Public Health's information (address, phone number, and contact person) will 
be placed on the outside of the cooler in a pouch. The graduate student who is also a 
Medical Technologist at UMC or the PI will accompany the materials at all times. 
Anyone transporting the isolates will have current DOT 6.2 Infectious Substance 
Training provided by RMS before transporting the biological culture material. The 
package will be and marked as a Category B Infectious Disease Substance. 
Decontamination/Clean-Up Procedures: Specifics on products and procedures used to 
clean work areas. Include specifics on when these procedures will be performed and 
timing involved (i.e. contact time): 
MRSA isolates will be transported from UMC hospital to UNLV MPE 231. All 
primary culture tubes will be individually labeled according to their contents and screw 
caps will be Para filmed. The primary tube will be placed inside a sealable bag that has a 
biohazard symbol on it with an absorbent packing material. The secondary bag will be 
placed in a rigid sturdy outer container with a lid. This rigid container will then be placed 
inside an insulated cooler that has a lid that snaps that prevents it from opening. Leak 
proof ice packs will be placed inside the cooler. A DOT Class 6.2 Infectious Substance 
and Biohazard label will be placed on the outside of the cooler. A bill of lading, Material 
Safety Data Sheet and an emergency contact sheet which includes the School of Public 
Health's information (address, phone number, and contact person) will be placed on the 
outside of the cooler in a pouch. The graduate student who is also a Medical Technologist 
at UMC or the PI will accompany the materials at all times. Anyone transporting the 
isolates will have current DOT 6.2 Infectious Substance Training provided by RMS 
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before transporting the biological culture material. The package will be and marked as a 
Category B Infectious Disease Substance. 
Waste Disposal Procedures: Include specifics on collection, deactivation and transport 
for disposal: 
Upon completion of each experiment, anything to be removed from the biological 
safety cabinet will be wiped with a 1% sodium hypochlorite-soaked paper towel, and the 
paper towel will be disposed in a biohazard bag. Gloves and arm sleeves will be 
removed while hands and arms are still within the biological safety cabinet and will be 
placed into a biohazard bag. All used biohazard bags will be taped shut. 
Biohazard bags containing materials from the biological safety cabinet will be 
transferred immediately to the dish room for autoclaving. Autoclaving of contaminated 
materials will be restricted to properly trained personnel. 
All personnel in the laboratory will wash their hands with soap and warm water for at 
least 20 seconds upon removing ones gloves and before leaving the laboratory. 
Spill Response Procedures: Procedures to follow if a spill occurs: 
Plastic squirt dispense bottles with a 1% sodium hypochlorite solution are 
strategically located throughout the laboratory for surface disinfection. If a biological 
spill were to occur, the area would be saturated with the disinfecting solution and soaked 
for a minimum of 30 minutes contact time. The area would then be wiped dry with paper 
towels. The paper towels would be discarded into a biohazard bag before autoclaving 
(see above). All laboratory personnel in the laboratory at the time of the spill will be 
notified of the event and the decontamination procedures being undertaken. The PI, If 
not present at the time of the spill, will be notified by telephone. 
Injury/Exposure Response Procedures: Steps to be taken in the event of an exposure 
incident: 
Three sinks are located in the laboratory for washing of any exposed skin that would 
come in contact with hazardous material. An eyewash station is located in the laboratory 
for flushing of eyes. A laboratory safety shower is located in the adjoining laboratory 
space for full body rinsing, if needed. Injury/exposure will be reported to the PI. 
Depending on the severity of the injury/exposure, the affected individual may chose to be 
transported to a local quick care or emergency room for treatment. UNLV Health and 
Safety will be notified of any significant injury/exposure warranting attendance of 
healthcare professionals. 
Unattended Operations: Portions of the experiment that may run unattended and steps 
taken to prevent accidental exposures: 
Petri plates are incubated unattended in the 35 degree incubator. The screw-capped 
vials containing a swab sample and the enrichment broth will also be incubated overnight 
in the same incubator. The incubator is double doored with an inner glass door and an 
outer door. The vials will be placed into a size appropriate test tube rack that is placed 
into a plastic basin to collect any figurative liquid should a spill occur. Should a Petri 
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plate lid become dislodged, this would be observed through the glass inner door before 
that door was opened. The individual would already be wearing gloves and a lab coat 
(see above). The lid would be replaced and all of the contents placed into a biohazard 
bag for transport to the biological safety cabinet where the exterior of each plate would 
be wiped with a 1% hypochlorite solution (see above). The interior of the incubator 
would be disinfected by wiping with a 1 % hypochlorite solution before being returned to 
service. If a liquid spill were to occur from the test tubes, the basin and its contents will 
be disinfected with a 1% sodium hypochlorite solution as described above in spill 
response procedures. Liquids stored in the double glass door or other refrigerators will 
be limited to sterile water, PBT, and the enrichment broth described above. No liquids 
containing live bacteria will be stored in the refrigerators. 
Additional Laboratory Specific Safety Procedures: 
1. Long hair will be tied back when working with or near an open flame. 
2. No make-up application in the laboratory. 
3. Contact lenses can be worn as long as the user wears safety glasses. 
4. No open toe shoes in the laboratory. 
5. End of the day laboratory lock-up requires a check to ensure that all propane 
torches, water bath, hot plates, centrifuges and unused laboratory equipment are 
turned off, incubators doors are sealed shut, and the laboratory doors are locked. 
Variations from UNLV Standard Biosafety Level 2 Practices and Procedures and 
Reasons: 
None. 
I have read and understood all portions of this SOP. I agree to contact the Principal 
Investigator should I have any questions or plan on making any modifications to the 
procedures detailed here. 
NAME 
Linda Stetzenbach 
Ilene Bautista 
Vanessa Stevens 
Janice Klaassen 
SIGNATURE DATE 
** Original copy of this document has been submitted to the UNLV's Institutional 
Biosafety Committee (IBC). 
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